In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
List view / Grid view
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
CRISPR holds great promise in advancing pharmacological research and has fuelled the rapid expansion of using gene-edited cells for drug discovery processes. CRISPR-Cas9 dropout screens have emerged as a useful tool for high-throughput large-scale loss-of-function screens, which seek to identify the relationship between genotype and phenotype. Dr Pushpanathan Muthuirulan, Research…
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
MIT researchers have shown that a combination of three drugs can eliminate pancreatic tumours in mice, possibly leading to new therapies.
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.
Researchers have developed a vaccine using stem cells that protected mice injected with pancreatic cancer cells from developing tumours.
Researchers have developed the first 3D organoid models of the pancreas that includes both the acinar and ductal structures.
High IFN signalling in pancreatic tumours are sensitive to NAMPT inhibitors which block a pathway in NAD synthesis, presenting a drug target.
Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
New research shows tissue damage to cells carrying KRAS mutations induces epigenetic changes that promote pancreatic cancer.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
In a new report, Elsevier describes how it used text mining to reveal the top trends in pancreatic cancer research – this article outlines the findings.
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.